These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 19763820)

  • 1. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
    Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
    Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
    Kabelitz D; Wesch D; Pitters E; Zöller M
    J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
    Chen J; Niu H; He W; Ba D
    Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
    Zhao H; Xi X; Cui L; He W
    Cell Mol Immunol; 2012 Mar; 9(2):147-54. PubMed ID: 21909128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
    Pereboeva L; Harkins L; Wong S; Lamb LS
    Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
    Liu Z; Guo B; Lopez RD
    J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
    Hoeres T; Smetak M; Pretscher D; Wilhelm M
    Front Immunol; 2018; 9():800. PubMed ID: 29725332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
    Liu Z; Noh HS; Chen J; Kim JH; Falo LD; You Z
    J Immunol; 2008 Sep; 181(6):4363-70. PubMed ID: 18768895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine T cell determination of pregnancy outcome: I. Effects of strain, alphabeta T cell receptor, gammadelta T cell receptor, and gammadelta T cell subsets.
    Arck PC; Ferrick DA; Steele-Norwood D; Croitoru K; Clark DA
    Am J Reprod Immunol; 1997 Jun; 37(6):492-502. PubMed ID: 9228307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells.
    Jensen SM; Meijer SL; Kurt RA; Urba WJ; Hu HM; Fox BA
    J Immunol; 2003 Feb; 170(4):2014-21. PubMed ID: 12574371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
    Cha E; Graham L; Manjili MH; Bear HD
    Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
    Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
    J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.
    Janssen A; Villacorta Hidalgo J; Beringer DX; van Dooremalen S; Fernando F; van Diest E; Terrizi AR; Bronsert P; Kock S; Schmitt-Gräff A; Werner M; Heise K; Follo M; Straetemans T; Sebestyen Z; Chudakov DM; Kasatskaya SA; Frenkel FE; Ravens S; Spierings E; Prinz I; Küppers R; Malkovsky M; Fisch P; Kuball J
    Cancer Immunol Res; 2020 Apr; 8(4):530-543. PubMed ID: 32019779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.